Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 217

1.

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder.

de Jong S, Diniz MJA, Saloma A, Gadelha A, Santoro ML, Ota VK, Noto C; Major Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, Curtis C, Newhouse SJ, Patel H, Hall LS, O Reilly PF, Belangero SI, Bressan RA, Breen G.

Commun Biol. 2018 Oct 8;1:163. doi: 10.1038/s42003-018-0155-y. eCollection 2018.

2.

Empirical evidence of the effect of personality pathology on the outcome of panic disorder.

Reich J, Schatzberg A, Delucchi K.

J Psychiatr Res. 2018 Dec;107:42-47. doi: 10.1016/j.jpsychires.2018.10.005. Epub 2018 Oct 5.

PMID:
30316085
3.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print]

PMID:
30283029
4.

Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders.

Gill SK, Gomez RG, Keller J, Schatzberg AF.

Psychiatry Res. 2018 Nov;269:733-739. doi: 10.1016/j.psychres.2018.09.003. Epub 2018 Sep 5.

PMID:
30273898
5.

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF.

Am J Psychiatry. 2018 Aug 29:appiajp201818020138. doi: 10.1176/appi.ajp.2018.18020138. [Epub ahead of print]

PMID:
30153752
6.

Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis.

Hagenauer MH, Schulmann A, Li JZ, Vawter MP, Walsh DM, Thompson RC, Turner CA, Bunney WE, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H.

PLoS One. 2018 Jul 17;13(7):e0200003. doi: 10.1371/journal.pone.0200003. eCollection 2018.

7.

Learning to actively cope with stress in female mice.

Lyons DM, Buckmaster CL, Schatzberg AF.

Psychoneuroendocrinology. 2018 Oct;96:78-83. doi: 10.1016/j.psyneuen.2018.06.010. Epub 2018 Jun 9.

PMID:
29909293
8.

Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes.

Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Electronic address: douglas.ruderfer@vanderbilt.edu; Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium.

Cell. 2018 Jun 14;173(7):1705-1715.e16. doi: 10.1016/j.cell.2018.05.046.

PMID:
29906448
9.

Connective Tissue Growth Factor Is a Novel Prodepressant.

Turner CA, Sharma V, Hagenauer MH, Chaudhury S, O'Connor AM, Hebda-Bauer EK, Thompson RC, Myers RM, Bunney WE, Barchas JD, Lee FS, Schatzberg AF, Watson SJ Jr, Akil H.

Biol Psychiatry. 2018 Oct 15;84(8):555-562. doi: 10.1016/j.biopsych.2018.04.013. Epub 2018 May 3.

10.

Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates.

Turner CA, Lyons DM, Buckmaster CL, Aurbach EL, Watson SJ, Schatzberg AF, Akil H.

Neuropsychopharmacology. 2018 Apr 9. doi: 10.1038/s41386-018-0052-6. [Epub ahead of print]

PMID:
29703997
11.

Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.

Rollins BL, Morgan L, Hjelm BE, Sequeira A, Schatzberg AF, Barchas JD, Lee FS, Myers RM, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP.

Mol Neuropsychiatry. 2018 Feb;3(3):157-169. doi: 10.1159/000484348. Epub 2017 Nov 30.

12.

Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response.

Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A.

Biol Psychiatry. 2018 Jul 1;84(1):46-54. doi: 10.1016/j.biopsych.2018.01.008. Epub 2018 Jan 31.

13.

High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression.

Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF.

Brain. 2018 Feb 5. doi: 10.1093/brain/awx379. [Epub ahead of print] No abstract available.

PMID:
29415152
14.

The Black Book of Psychotropic Dosing and Monitoring.

Schatzberg AF, Charles D.

Psychopharmacol Bull. 2018 Jan 15;48(1):64-153. No abstract available.

PMID:
29382960
15.

Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression.

Davis EG, Keller J, Hallmayer J, Pankow HR, Murphy GM Jr, Gotlib IH, Schatzberg AF.

Transl Psychiatry. 2018 Jan 10;8(1):5. doi: 10.1038/s41398-017-0051-0. Review.

16.

Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.

O'Connell CP, Goldstein-Piekarski AN, Nemeroff CB, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, Dunlop BW, Craighead WE, Mayberg HS, Williams LM.

Am J Psychiatry. 2018 Mar 1;175(3):251-261. doi: 10.1176/appi.ajp.2017.17020172. Epub 2017 Dec 15.

PMID:
29241359
17.

Stress amplifies sex differences in primate prefrontal profiles of gene expression.

Lee AG, Hagenauer M, Absher D, Morrison KE, Bale TL, Myers RM, Watson SJ, Akil H, Schatzberg AF, Lyons DM.

Biol Sex Differ. 2017 Nov 2;8(1):36. doi: 10.1186/s13293-017-0157-3.

18.

Post-mortem molecular profiling of three psychiatric disorders.

Ramaker RC, Bowling KM, Lasseigne BN, Hagenauer MH, Hardigan AA, Davis NS, Gertz J, Cartagena PM, Walsh DM, Vawter MP, Jones EG, Schatzberg AF, Barchas JD, Watson SJ, Bunney BG, Akil H, Bunney WE, Li JZ, Cooper SJ, Myers RM.

Genome Med. 2017 Jul 28;9(1):72. doi: 10.1186/s13073-017-0458-5.

19.

Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.

Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A.

J Clin Psychopharmacol. 2017 Oct;37(5):505-511. doi: 10.1097/JCP.0000000000000744.

20.

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments.

JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Review.

PMID:
28249076

Supplemental Content

Loading ...
Support Center